Clicky

Axim Biotechnologies(AXIM)

Description: AXIM Biotechnologies, Inc., formerly Axim International, Inc., is a biotechnology company. The Company is engaged in developing the treatment of pain, spasticity, anxiety and other medical disorders with the application of cannabinoids-based products. It is focused on research, development and production of pharmaceutical, nutriceutical and cosmetic products, as well as procurement of genetically and nano-controlled active ingredients. It is engaged in the business of research, development and production of alternative and renewable sources of energy, such as high caloric content fuels produced from industrial hemp and from the byproducts of industrial hemp after completion of the oil extraction/decarboxylation process. It is engaged in the research and development of pharmaceutical delivery systems and active pharmaceutical ingredients (API) for treatment of conditions, such as Parkinson's disease, Alzheimer's disease, restless leg syndrome (RLS) and Crohn's disease.


Keywords: Medicine Biotechnology Pain Health Sciences Active Pharmaceutical Ingredients Hemp Herbs Alzheimer's Disease Parkinson's Disease Cosmetic Products Crohn's Disease Pharmaceutical Ingredients Active Ingredients Active Pharmaceutical Ingredient Anxiety Delivery Systems Oil Extraction Medical Disorders

Home Page: www.aximbiotech.com

6191 Cornerstone Court, East
San Diego, CA 92121
United States
Phone: 858 923 4422


Officers

Name Title
Mr. John W. Huemoeller II Pres, CEO & Director
Mr. Robert T. Malasek CFO & Sec.
Ms. Catalina Valencia J.D. Co-Founder & CEO of Sapphire Biotech, Inc.
Dr. Sergei A. Svarovsky M.B.A., Ph.D. Chief Scientific Officer & Co-Founder of Sapphire Biotech, Inc.
Dr. Alim Seit-Nebi Ph.D. CTO & Co-Founder of Sapphire Biotech, Inc.
Mr. Jeffrey A. Busby Sr. VP of Bus. Devel.
Dr. Joseph Tauber M.D. Chief Medical Officer & Chairman of the Medical Advisory Board

Exchange: OTCQB

Country: US : United States of America

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 2.8584
Price-to-Sales TTM: 943.933
IPO Date:
Fiscal Year End: December
Full Time Employees: 6
Back to stocks